<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02799095</url>
  </required_header>
  <id_info>
    <org_study_id>ALK4230-A101</org_study_id>
    <nct_id>NCT02799095</nct_id>
  </id_info>
  <brief_title>A Study of the Effects of ALKS 4230 on Subjects With Solid Tumors</brief_title>
  <official_title>A Phase I Study of ALKS 4230 in Subjects With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alkermes, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alkermes, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To better understand the safety and tolerability of ALKS 4230 in humans
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Characterization of adverse events (AEs) and dose-limiting toxicities (DLT) in study Part A</measure>
    <time_frame>From time of initiation of therapy until 30 days after last dose of study drug, assessed up to 24 months</time_frame>
    <description>Incidence of AEs that are both serious and drug-related</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of drug-related AEs in study Part B</measure>
    <time_frame>From time of initiation of therapy until 30 days after last dose of study drug, assessed up to 24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR) based on investigator review of radiographic or photographic images</measure>
    <time_frame>From time of initiation of therapy until the date of first documented tumor progression, assessed up to 24 months</time_frame>
    <description>Proportion of subjects with objective evidence of Complete Response (CR/irCR) or Partial Response (PR/irPR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate</measure>
    <time_frame>From time of initiation of therapy until the date of first documented tumor progression, assessed up to 24 months</time_frame>
    <description>Proportion of subjects with objective evidence of CR, PR, or Stable Disease (SD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response in subjects with CR or PR</measure>
    <time_frame>From time of initiation of therapy until the date of first documented tumor progression, assessed up to 24 months</time_frame>
    <description>Time from the first documentation of response (CR or PR) to the first documentation of objective tumor progression or death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentrations of ALKS 4230 will be determined at various time points</measure>
    <time_frame>From time of initiation of therapy until the last treatment cycle, assessed up to 24 months</time_frame>
    <description>Concentration vs time and standard pharmacokinetic (PK) parameters will be summarized by dose level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum will be assayed for the presence of anti-ALKS 4230 antibodies</measure>
    <time_frame>From time of initiation of therapy until the last treatment cycle, assessed up to 24 months</time_frame>
    <description>Results will be summarized by dose level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunophenotyping of peripheral blood mononuclear cells will be performed by flow cytometry at various time points</measure>
    <time_frame>From time of initiation of therapy until the last treatment cycle, assessed up to 24 months</time_frame>
    <description>Results will be summarized by dose level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentrations of proinflammatory cytokines will be assessed using a multiplex method at various time points</measure>
    <time_frame>From time of initiation of therapy during the first two treatment cycles, assessed up to 2 months</time_frame>
    <description>Results will be summarized by dose level</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <arm_group>
    <arm_group_label>ALKS 4230</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALKS 4230</intervention_name>
    <description>Intravenous infusion over 30 minutes given daily for 5 consecutive days followed by an off-treatment period</description>
    <arm_group_label>ALKS 4230</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  For Part A, the subject has histological or cytological evidence of a solid tumor; for
             Part B, the subject has histological or cytological evidence of 1 of the following
             solid tumor types: melanoma, renal cell carcinoma, or ovarian cancer

          -  All subjects must have advanced solid tumors that have returned after treatment with
             established approved therapies or be intolerant of established therapies

          -  Subjects enrolled in Part B must have at least 1 lesion that may qualify as a target
             lesion

          -  Subject can move around on their own, has an Eastern Cooperative Oncology Group (ECOG)
             performance status of 0 or 1, and has an estimated life expectancy of at least 3
             months

          -  Subject must have adequate hematologic reserve

          -  Subjects must have adequate liver function

          -  Subjects must have adequate kidney function

          -  Subjects must be recovered from the effects of any prior chemotherapy, immunotherapy,
             other prior systemic anticancer therapy, radiotherapy or surgery

          -  Subjects who have received investigational agents must wait at least 4 weeks

          -  Females of childbearing potential must have a negative pregnancy test within 7 days of
             the start of treatment and on Day 1 before the first dose is administered. A female
             not of childbearing potential is one who has undergone bilateral oophorectomies or who
             is postmenopausal, defined as &gt;45 years of age and without a menstrual period for 12
             consecutive months

          -  Meets contraceptive requirements defined in the protocol

          -  Additional criteria may apply

        Exclusion Criteria:

          -  Subject is currently pregnant or breastfeeding, or is planning to become pregnant
             during the study

          -  Subjects with an active infection or with a fever &gt;/+ 38.5 degrees C within 3 days of
             the first scheduled day of dosing for Cycle 1

          -  Subjects with active or symptomatic central nervous system metastases are excluded.
             Subjects with central nervous system metastases are eligible for the study if the
             metastases have been treated by surgery and/or radiation therapy, the subject is off
             corticosteroids for at least 2 weeks and the subject is neurologically stable

          -  Subjects have a mean QT interval corrected by the Fridericia Correction formula value
             of &gt;470 msec (in females) or &gt;450 msec (in males)

          -  Subjects with known hypersensitivity to any components of ALKS 4230

          -  Subjects who require pharmacologic doses of corticosteroids; replacement doses,
             topical, ophthalmologic, and inhalational steroids are permitted

          -  Subjects who developed autoimmune disorders while on prior immunotherapy, including
             pneumonitis, nephritis, and neuropathy

          -  Subjects with any other concurrent uncontrolled illness, including mental illness or
             substance abuse, which may interfere with the ability of the subject to cooperate and
             participate in the study

          -  The subject is known to be positive for human immunodeficiency virus (HIV), hepatitis
             B or C

          -  Additional criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lisa von Moltke, MD</last_name>
    <role>Study Director</role>
    <affiliation>Alkermes, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sean Rossi</last_name>
    <phone>781-609-6013</phone>
    <email>Sean.Rossi@alkermes.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Alkermes Investigational Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alkermes Investigational Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alkermes Investigational Site</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>47201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alkermes Investigational Site</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alkermes Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alkermes Investigational Site - 2 Sites</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 1, 2016</study_first_submitted>
  <study_first_submitted_qc>June 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 14, 2016</study_first_posted>
  <last_update_submitted>February 2, 2018</last_update_submitted>
  <last_update_submitted_qc>February 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Immunotherapy</keyword>
  <keyword>IL-2</keyword>
  <keyword>Interleukin-2</keyword>
  <keyword>Solid tumors</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

